We Manufacture Products That Change Lives™
Life changing perinatal tissue allografts based on our proprietary BioREtain® process.
Best-In-Class Perinatal Tissue Allografts
- BioStem Technologies® produces innovative perinatal tissue-based allografts.
- Our membrane allografts are manufactured using our proprietary BioREtain® processing method that preserves the quality of the tissue.
- In our AATB® accredited, FDA® registered, cGMP compliant lab, we strive to provide products and services that adhere to Current Good Tissue Practice requirements.
Best-In-Class Perinatal Tissue Allografts
- BioStem Technologies® produces innovative perinatal tissue-based allografts.
- Our membrane allografts are processed using our proprietary BioREtain® processing method that preserves the biologic quality of the tissue.
- In our AATB® accredited, FDA® registered, cGMP compliant lab, we strive to provide products and services that adhere to Current Good Tissue Practice requirements.
Why Choose Us
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.
Our allografts are processed utilizing our proprietary BioREtain® method, which focuses on preserving the tissue’s endogenous biological properties while maintaining the structure and matrix found in fresh perinatal tissue.
BioStem is committed to improving patients’ quality of life through scientific innovation and strict adherence to our quality system.
Latest News
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million
POMPANO BEACH, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) —BioStem Technologies, Inc.(OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced selected preliminary financial results for the fiscal fourth quarter and full year ended December 31, 2024. 2024 Preliminary Fourth Quarter and Year End Results: “2024 has been an extraordinary and transformative year for BioStem,…
Subscribe To Our Newsletter
To stay up to date on all of our news, products, and achievements, please subscribe to our newsletter.
